Cancer vaccine maker Aduro files for $86M IPO

Aduro Biotech is the latest to try its hand at an IPO, and it laid out its case for an $86 million IPO last week. Central to its pitch: Phase IIa data for CRS-207 combined with once-failed cancer vaccine GVAX. That study was stopped early on promising data, winning the FDA over to grab a breakthrough therapy designation. More